supplement vitamin D will alleviate OAB symptoms in patient with low Vitamin D Overactive bladder , low vitamin D
Conditions
Interventions
Placebo oral tablet, identical in appearance, color, size and composition to the Vitamin D2 tablet, administered once weekly for 12 weeks, in addition to standard behavioral modification therapy for o
Placebo Comparator Drug,Experimental Drug
placebo group,Vitamin D group
Sponsors
Faculty of Medicine, Thammasat University, Thailand
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1.Patients aged between 18-70 years 2.Patients diagnosed with overactive bladder (OAB), defined as a symptom complex consisting of urinary urgency with urinary frequency or nocturia, with or without urgency urinary incontinence, in the absence of urinary tract infection or other identifiable pathology of the lower urinary tract 3.Patients with serum 25-hydroxyvitamin D level less than 30 ng/mL (less than 75 nmol/L), measured after the diagnosis of overactive bladder has been established 4.Patients who are able to cooperate and comprehend the study questionnaires, and are able to read Thai 5.Patients who are able to attend blood collection for Vitamin D level measurement at Thammasat University Hospital 6.Patients with an estimated glomerular filtration rate (eGFR) of 30 mL/min/1.73m2 or greater
Exclusion criteria
Exclusion criteria: Exclusion Criteria 1.Patients who are unable to complete the overactive bladder assessment questionnaire, such as those who cannot read or comprehend Thai, or those with visual impairment 2.Patients with neurological or spinal cord disorders affecting bladder function (neurogenic bladder), such as spinal cord injury, multiple sclerosis, or Parkinson's disease 3.Patients with pelvic organ prolapse 4.Patients with bladder outlet obstruction 5.Patients with hematuria 6.Patients with post-void residual urine volume greater than 100 mL 7.Patients receiving medications that affect bladder function 8.Patients diagnosed with interstitial cystitis or bladder cancer 9.Patients with maximum urinary flow rate (Qmax) less than 10 mL/s 10.Patients who have received anticholinergics or beta-3 agonists within 4 weeks prior to enrollment, Vitamin D supplementation greater than 800 IU/day within 8 weeks prior to enrollment, or calcium channel blockers or diuretics (unless on a stable dose for 3 months or longer) 11.Female patients who are pregnant or breastfeeding 12.Patients with active urinary tract infection 13.Patients with a history of anti-incontinence surgery, bladder surgery, or bladder calculi 14.Patients with a history of pelvic irradiation 15.Patients with serum calcium level greater than 10.5 mg/dL
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| overactive bladder symptom scores 3 month after treatment overactive bladder symptom scores | — |
Secondary
| Measure | Time frame |
|---|---|
| relationship betweem OAB symptom And vitamin D level At baseline (Week 0), Week 6, and Week 12 level of Vitamin D & OABSS | — |
Countries
Thailand
Contacts
Public ContactAtthaphong Atthaphong
Department of Surgery, Faculty of Medicine, Thammasat University (Chalermphrakiat), Pathum Thani, Thailand
Outcome results
None listed